methoxymethyllithium | 14704-15-5

• 分子结构分类: 有机化合物 - 有机盐 - 有机金属盐
• 英文名称: methoxymethyllithium
• 英文别名: methoxymethyl-lithium；[(methyl)oxy]methyllithium
• CAS: 14704-15-5
• 化学式: C₂H₅LiO
• 分子量: 52.0021
• InChiKey: ATOMTHYGEJDUAK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.04
• 重原子数：
  4
• 可旋转键数：
  0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  methoxymethyllithium 在 四氯化硅 、 二甲醇缩甲醛 作用下， 生成 tetrakis-methoxymethyl-silane
  参考文献：
  名称：

  Schoellkopf,U.; Traenckner,H.-J., Journal of Organometallic Chemistry, 1966, vol. 5, p. 300

  摘要：

  DOI：
• 作为产物：
  描述：

  正丁基锂 、 氯甲基甲基醚 生成 methoxymethyllithium
  参考文献：
  名称：

  COREY, E. J.;ECKRICH, T. M., TETRAHEDRON. LETT., 1983, 24, N 31, 3163-3164

  摘要：

  DOI：

文献信息

• A novel method for generation of enolizable N-trimethylsilylaldimines and application to β-lactam synthesis
  作者：Tadao Uyehara、Ichiro Suzuki、Yoshinori Yamamoto

  DOI：10.1016/s0040-4039(01)80709-7

  日期：1989.1

  A new method to generate N-trimethylsilylaldimines has been developedby the combination of bis(trimethylsilyl)formamide and organolithium reagents and applied successfully to β-lactam synthesis.

  通过双（三甲基甲硅烷基）甲酰胺和有机锂试剂的结合，开发了一种新的生成N-三甲基甲硅烷基亚胺的方法，并成功地应用于β-内酰胺的合成。
• 2-(2-Pyridyl)ethylsilyl Group as a New Class of Electroauxiliary. Fine Tuning of the Electron Transfer Driven Reactions by the Dynamic Coordination to Silicon
  作者：Jun-ichi Yoshida、Seiji Suga、Ken-ichi Fuke、Mitsuru Watanabe

  DOI：10.1246/cl.1999.251

  日期：1999.3

  The introduction of 2-(2-pyridyl)ethyl group on silicon decreases the oxidation potentials of silyl-substituted heteroatom compounds. The molecular orbital calculations indicate that this effect is attributed to the dynamic coordination of the pyridyl group to silicon in the cation radical intermediate. Such coordination also facilitates the selective C-Si bond cleavage.

  在硅上引入 2-(2-吡啶基)乙基降低了甲硅烷基取代的杂原子化合物的氧化电位。分子轨道计算表明，这种效应归因于阳离子自由基中间体中吡啶基与硅的动态配位。这种配位也有利于选择性的 C-Si 键断裂。
• N3 alkylated benzimidazole derivatives as MEk inhibitors
  申请人：Wallace M. Eli

  公开号：US20050143438A1

  公开（公告）日：2005-06-30

  Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein W, R 1 , R 2 , R 7 , R 8 , R 9 and R 10 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed is a method of using such compounds in the treatment of hyperproliferative diseases in mammals, and pharmaceutical compositions containing such compounds.

  本发明涉及公式I的化合物及其药学上可接受的盐和前药，其中W、R1、R2、R7、R8、R9和R10如规范中所定义。这些化合物是MEK抑制剂，对哺乳动物的高增殖性疾病，如癌症和炎症的治疗有用。本发明还涉及使用这些化合物治疗哺乳动物高增殖性疾病的方法，以及含有这些化合物的制药组合物。
• N3 alkylated benzimidazole derivatives as MEK inhibitors
  申请人：——

  公开号：US20040116710A1

  公开（公告）日：2004-06-17

  Disclosed are compounds of the formula I 1 and pharmaceutically acceptable salts and prodrugs thereof, wherein W, R 1 , R 2 , R 7 , R 8 , R 9 and R 10 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed is a method of using such compounds in the treatment of hyperproliferative diseases in mammals, and pharmaceutical compositions containing such compounds.

  本发明涉及公式I1的化合物及其药学上可接受的盐和前药，其中W、R1、R2、R7、R8、R9和R10如规范中所定义。这些化合物是MEK抑制剂，可用于哺乳动物的增殖过度性疾病的治疗，如癌症和炎症。本发明还涉及使用这些化合物治疗哺乳动物的增殖过度性疾病的方法，以及含有这些化合物的制药组合物。
• N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS
  申请人：Wallace Eli M.

  公开号：US20080177082A1

  公开（公告）日：2008-07-24

  Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein W, R 1 , R 2 , R 7 , R 8 , R 9 and R 10 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed is a method of using such compounds in the treatment of hyperproliferative diseases in mammals, and pharmaceutical compositions containing such compounds.

  本发明涉及公式I的化合物及其药学上可接受的盐和前药，其中W，R1，R2，R7，R8，R9和R10如规范所定义。这些化合物是MEK抑制剂，在哺乳动物的治疗高增殖性疾病，如癌症和炎症中有用。本发明还涉及使用这些化合物治疗哺乳动物的高增殖性疾病的方法，以及含有这些化合物的药物组合物。